NAFLD VS MAFLD. The evidence-based debate has come. Time to change?

Annals of Hepatology, Journal Year: 2022, Volume and Issue: 27(6), P. 100765 - 100765

Published: Sept. 28, 2022

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the world's adult population and is linked to metabolic syndrome. It can progress steatohepatitis, cirrhosis hepatocellular carcinoma. During last four decades, it has been subject exhaustive research in multiple aspects define its epidemiology, pathophysiological mechanisms therapy. In 2020, a group international experts proposed change name metabolic-associated (MAFLD) with main objective making an inclusive diagnosis prioritizing abnormalities. However, terminology included modification diagnostic criteria allowing non-exclusion other concomitant diseases such as alcohol disease, chronic hepatitis B or C. The proposal precipitated wave debates among based on theoretical opinions desirability rapid adoption new terminology. But also epidemiological clinical studies which, two years later, have provided evidence differences similarities entities, specially, those that could be considered for future refinements MAFLD. Likewise, this may contribute deciding time text, we discuss, general terms, important generated date cross-sectional longitudinal focusing characteristics outcomes, mainly all-cause specific mortality

Language: Английский

---

Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study

Hepatology International, Journal Year: 2022, Volume and Issue: 17(1), P. 202 - 214

Published: Oct. 4, 2022

Metabolic dysfunction-associated fatty liver disease (MAFLD) is recently recognized as a condition featured with metabolic dysfunctions in liver. It has been supposed that MAFLD might contribute to the development of IBD, but evidence from prospective cohort studies lacking and inconclusive.A total 221,546 females 183,867 males UK Biobank enrolled 2006-2010 were included examine whether function markers related incident IBD. was identified based on hepatic steatosis defined by index plus prevalence overweight, type 2 diabetes mellitus, or at least two abnormalities. Biomarker (albumin [ALB], alkaline phosphatase [ALP], alanine transaminase [ALT], aspartate [AST]; gamma-glutamyl transferase [GGT], bilirubin [TB], protein [TP]) measured using colorimetric enzymatic assays. The incidence IBD ascertained primary care inpatient records. Cox proportional hazard model used estimate ratios (HRs) 95% confidence intervals (CI) for magnitude their associations.With mean follow-up 12.1 years, 2228 cases documented. We 150,385 individuals baseline 86% participants' circulating within normal range. Participants associated 12% (HR 1.12, CI 1.03, 1.23, p = 0.012) increased risk compared those without baseline; association stronger (p-Heterogeneity 0.006) Crohn's 1.35, 1.15, 1.59, < 0.001) than ulcerative colitis 0.93, 0.57). As serum markers, HRs per 1-SD increment ALB, ALP, AST, TB concentration 0.86 (95% 0.83, 0.90, 0.001), 1.18 1.13, 1.24, 0.95 0.91, 0.99, 0.027), 0.92 0.87, 0.96, respectively. did not observe significant associations GGT TP IBD.Individuals developing especially CD, UC. Circulating levels biomarkers surrogate indicators also risk.

Language: Английский

---

Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease

Therapeutic Advances in Endocrinology and Metabolism, Journal Year: 2022, Volume and Issue: 13

Published: Jan. 1, 2022

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic (NAFLD), which exclusion diagnosis, MAFLD defined by a set positive criteria. This recent change in terminology challenging because and NAFLD denote two similar, albeit not identical, clinical populations. When diagnostic criteria for are applied, histology appears more severe outcomes less favorable. However, management remains similar. While biopsy still reference standard achieving final noninvasive imaging- or biomarker-based modalities currently gaining momentum. should be recommended when challenges exist. In this review, we compared epidemiology, natural history, diagnosis respect to traditional definition.

Language: Английский

---

The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population

Journal of Cachexia Sarcopenia and Muscle, Journal Year: 2022, Volume and Issue: 13(6), P. 2953 - 2960

Published: Oct. 12, 2022

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) emphasizes the metabolic dysfunction in nonalcoholic (NAFLD). Although relationship between low muscle mass and NAFLD has been suggested, effect of MAFLD on is yet to be investigated. In this study, we examined an asymptomatic Korean population.Examinees who underwent FibroScan® bioelectrical impedance analyses same day during period June 2017 December 2019 were included. Hepatic steatosis was diagnosed using controlled attenuation parameter (CAP) with two cut-off values 248 294 dB/m. Low defined based appendicular skeletal mass/body weight (wt) or body index (BMI) ratios standard deviations below sex-specific mean for healthy young adults. Subjects divided into four subgroups: diabetic (presence diabetes mellitus [DM]), (MD) (≥2 abnormalities without DM), overweight (overweight/obese DM <2 abnormalities) no MAFLD.Among all 6414 subjects (mean 53.9 years age; 85.4% male), prevalence 49.9% 22.7% CAP dB/m, respectively. multivariate analysis, associated increased risk both mass_wt (odds ratio [OR] 1.80, 95% confidence interval [CI] 1.38-2.35, P < 0.001) mass_BMI (OR 1.31, CI 1.01-1.70, = 0.042). The most subgroup compared no-MAFLD group 2.11, 1.51-2.96, 0.001 OR 1.51, 1.08-2.13, 0.017). There MD 1.73, 1.31-2.28, 0.001). Comparable results observed when value dB/m applied.The presence significantly varying risks according subgroups. Clinicians should aware differentiated across subgroups MAFLD.

Language: Английский

---

Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study

Lipids in Health and Disease, Journal Year: 2023, Volume and Issue: 22(1)

Published: Oct. 28, 2023

Abstract Background Variations in the prevalence and systemic inflammatory (SI) status between non-alcoholic fatty liver disease (NAFLD) newly defined metabolic dysfunction-associated (MAFLD) have only been reported by few studies. Hence, this study aimed to compile data on inflammation levels of MAFLD NAFLD a general population from Southeast China was summarized explore potential effect transformation definition. Methods A total 6718 participants aged 35–75 were enrolled. Logistic regression restricted cubic spline (RCS) models used examine relationship 15 SI indicators MAFLD. The predicted values analyzed using receiver operating characteristic (ROC) curve. Results 34.7% 32.4%, respectively. Their overlapping rate 89.7%, while 8.3% 1.9% MAFLD-only NAFLD-only. Among three FLD groups, group had highest 8 indicators, including CRP, WBC, LYMPH, NEUT, MONO, ALB, NLR, SIRI. non-FLD lower all compared with subgroups. odds ratios (ORs) 10 significant both multivariable-adjusted logistic RCS analyses or NAFLD, PLR, LMR, ALI CA. ROC analysis showed that AUC than 0.7 NAFLD. Conclusions could cover more severe status, whereas NAFLD-only exhibited levels. Moreover, there not high sensitivity suggesting are good diagnose NAFLD/MAFLD.

Language: Английский

---